Immatics Historical Financial Ratios

IMTXW Stock

USD 0.50 0.10 25.00%

Immatics Biotechnologies is lately reporting on over 76 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 3.58 or Days Sales Outstanding of 57.65 will help investors to properly organize and evaluate Immatics Biotechnologies financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in immatics biotechnologies GmbH. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

About Immatics Financial Ratios Analysis

Immatics BiotechnologiesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Immatics Biotechnologies investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Immatics financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Immatics Biotechnologies history.

Immatics Biotechnologies Financial Ratios Chart

At this time, Immatics Biotechnologies' POCF Ratio is fairly stable compared to the past year. Capex To Operating Cash Flow is likely to climb to 1.78 in 2024, despite the fact that Free Cash Flow Yield is likely to grow to (0.02).

Price To Sales Ratio Ptb Ratio Days Sales Outstanding Free Cash Flow Yield Invested Capital

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Immatics Biotechnologies stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Immatics Biotechnologies sales, a figure that is much harder to manipulate than other immatics biotechnologies GmbH multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Invested Capital

Invested capital represents the total cash investment that shareholders and debt holders have contributed to immatics biotechnologies GmbH. There are two different methods for calculating Immatics Biotechnologies invested capital: operating approach and financing approach. Understanding Immatics Biotechnologies invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.

Most ratios from Immatics Biotechnologies' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Immatics Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in immatics biotechnologies GmbH. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

	2021	2022 (projected)
Payables Turnover	29.1	26.53
Days Of Inventory On Hand	4.0E-6	3.0E-6

Payables Turnover Days Of Inventory On Hand

Immatics Biotechnologies fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		-0.96	0.99	-0.78	0.28	0.2	-0.7	-0.96	1.0	0.31	0.9	0.83	0.4	-0.44	-0.8	-0.83	-0.49	-0.87	0.38	-1.0	-0.47	0.79	0.87	-0.49	0.89	0.54
Ptb Ratio	-0.96		-0.98	0.7	-0.42	-0.37	0.65	1.0	-0.96	-0.47	-0.98	-0.88	-0.44	0.34	0.88	0.88	0.45	0.79	-0.46	0.96	0.4	-0.76	-0.92	0.53	-0.97	-0.62
Days Sales Outstanding	0.99	-0.98		-0.73	0.28	0.23	-0.6	-0.98	0.99	0.32	0.93	0.88	0.38	-0.41	-0.86	-0.88	-0.38	-0.86	0.49	-0.99	-0.36	0.72	0.9	-0.55	0.92	0.64
Book Value Per Share	-0.78	0.7	-0.73		-0.21	-0.09	0.8	0.7	-0.78	-0.22	-0.6	-0.75	-0.31	0.13	0.68	0.76	0.62	0.9	0.03	0.73	0.65	-0.79	-0.79	0.68	-0.6	-0.12
Free Cash Flow Yield	0.28	-0.42	0.28	-0.21		0.98	-0.33	-0.42	0.29	0.99	0.51	0.47	0.92	-0.47	-0.48	-0.46	-0.37	-0.25	0.31	-0.26	-0.09	0.34	0.48	-0.09	0.6	0.34
Operating Cash Flow Per Share	0.2	-0.37	0.23	-0.09	0.98		-0.17	-0.37	0.21	0.99	0.49	0.45	0.86	-0.43	-0.49	-0.44	-0.2	-0.16	0.43	-0.19	0.08	0.19	0.45	-0.12	0.58	0.43
Capex To Depreciation	-0.7	0.65	-0.6	0.8	-0.33	-0.17		0.65	-0.7	-0.32	-0.59	-0.47	-0.34	0.07	0.38	0.5	0.96	0.65	0.34	0.68	0.94	-0.98	-0.55	0.2	-0.57	0.17
Pb Ratio	-0.96	1.0	-0.98	0.7	-0.42	-0.37	0.65		-0.96	-0.47	-0.98	-0.88	-0.44	0.34	0.88	0.88	0.45	0.79	-0.46	0.96	0.4	-0.76	-0.92	0.53	-0.97	-0.62
Ev To Sales	1.0	-0.96	0.99	-0.78	0.29	0.21	-0.7	-0.96		0.32	0.9	0.83	0.42	-0.45	-0.8	-0.83	-0.49	-0.87	0.38	-1.0	-0.47	0.79	0.87	-0.48	0.89	0.54
Free Cash Flow Per Share	0.31	-0.47	0.32	-0.22	0.99	0.99	-0.32	-0.47	0.32		0.57	0.52	0.88	-0.42	-0.54	-0.51	-0.34	-0.26	0.36	-0.3	-0.07	0.35	0.53	-0.16	0.65	0.39
Roic	0.9	-0.98	0.93	-0.6	0.51	0.49	-0.59	-0.98	0.9	0.57		0.86	0.47	-0.32	-0.88	-0.86	-0.42	-0.7	0.51	-0.91	-0.33	0.71	0.9	-0.5	0.99	0.65
Inventory Turnover	0.83	-0.88	0.88	-0.75	0.47	0.45	-0.47	-0.88	0.83	0.52	0.86		0.49	-0.32	-0.97	-1.0	-0.25	-0.88	0.56	-0.81	-0.19	0.57	0.99	-0.79	0.88	0.67
Net Income Per Share	0.4	-0.44	0.38	-0.31	0.92	0.86	-0.34	-0.44	0.42	0.88	0.47	0.49		-0.76	-0.48	-0.48	-0.33	-0.41	0.38	-0.38	-0.07	0.34	0.49	-0.06	0.59	0.41
Days Of Inventory On Hand	-0.44	0.34	-0.41	0.13	-0.47	-0.43	0.07	0.34	-0.45	-0.42	-0.32	-0.32	-0.76		0.32	0.31	0.0	0.38	-0.55	0.43	-0.18	-0.1	-0.31	-0.12	-0.42	-0.57
Payables Turnover	-0.8	0.88	-0.86	0.68	-0.48	-0.49	0.38	0.88	-0.8	-0.54	-0.88	-0.97	-0.48	0.32		0.96	0.15	0.77	-0.66	0.79	0.09	-0.49	-0.98	0.8	-0.9	-0.76
Average Inventory	-0.83	0.88	-0.88	0.76	-0.46	-0.44	0.5	0.88	-0.83	-0.51	-0.86	-1.0	-0.48	0.31	0.96		0.28	0.89	-0.53	0.81	0.22	-0.59	-0.98	0.77	-0.88	-0.64
Capex To Revenue	-0.49	0.45	-0.38	0.62	-0.37	-0.2	0.96	0.45	-0.49	-0.34	-0.42	-0.25	-0.33	0.0	0.15	0.28		0.44	0.52	0.47	0.96	-0.91	-0.33	-0.03	-0.39	0.37
Cash Per Share	-0.87	0.79	-0.86	0.9	-0.25	-0.16	0.65	0.79	-0.87	-0.26	-0.7	-0.88	-0.41	0.38	0.77	0.89	0.44		-0.27	0.84	0.44	-0.7	-0.87	0.64	-0.71	-0.41
Pocfratio	0.38	-0.46	0.49	0.03	0.31	0.43	0.34	-0.46	0.38	0.36	0.51	0.56	0.38	-0.55	-0.66	-0.53	0.52	-0.27		-0.39	0.62	-0.2	0.52	-0.39	0.56	0.98
Interest Coverage	-1.0	0.96	-0.99	0.73	-0.26	-0.19	0.68	0.96	-1.0	-0.3	-0.91	-0.81	-0.38	0.43	0.79	0.81	0.47	0.84	-0.39		0.45	-0.78	-0.85	0.45	-0.89	-0.56
Capex To Operating Cash Flow	-0.47	0.4	-0.36	0.65	-0.09	0.08	0.94	0.4	-0.47	-0.07	-0.33	-0.19	-0.07	-0.18	0.09	0.22	0.96	0.44	0.62	0.45		-0.89	-0.27	0.03	-0.28	0.47
Pfcf Ratio	0.79	-0.76	0.72	-0.79	0.34	0.19	-0.98	-0.76	0.79	0.35	0.71	0.57	0.34	-0.1	-0.49	-0.59	-0.91	-0.7	-0.2	-0.78	-0.89		0.64	-0.25	0.68	-0.02
Days Payables Outstanding	0.87	-0.92	0.9	-0.79	0.48	0.45	-0.55	-0.92	0.87	0.53	0.9	0.99	0.49	-0.31	-0.98	-0.98	-0.33	-0.87	0.52	-0.85	-0.27	0.64		-0.78	0.91	0.64
Income Quality	-0.49	0.53	-0.55	0.68	-0.09	-0.12	0.2	0.53	-0.48	-0.16	-0.5	-0.79	-0.06	-0.12	0.8	0.77	-0.03	0.64	-0.39	0.45	0.03	-0.25	-0.78		-0.49	-0.44
Roe	0.89	-0.97	0.92	-0.6	0.6	0.58	-0.57	-0.97	0.89	0.65	0.99	0.88	0.59	-0.42	-0.9	-0.88	-0.39	-0.71	0.56	-0.89	-0.28	0.68	0.91	-0.49		0.69
Ev To Operating Cash Flow	0.54	-0.62	0.64	-0.12	0.34	0.43	0.17	-0.62	0.54	0.39	0.65	0.67	0.41	-0.57	-0.76	-0.64	0.37	-0.41	0.98	-0.56	0.47	-0.02	0.64	-0.44	0.69

Click cells to compare fundamentals

Immatics Biotechnologies Account Relationship Matchups

Immatics Biotechnologies fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	31.62	13.56	21.39	3.16	14.21	13.5
Ptb Ratio	(13.94)	4.06	30.9	2.57	3.41	3.58
Days Sales Outstanding	53.87	34.14	7.16	4.52	38.78	57.65
Book Value Per Share	(0.65)	2.17	0.38	3.17	2.79	2.93
Free Cash Flow Yield	0.12	(0.22)	(0.12)	0.17	(0.0166)	(0.0158)
Operating Cash Flow Per Share	1.13	(1.78)	(1.3)	1.49	0.23	0.24
Stock Based Compensation To Revenue	0.0462	0.73	0.76	0.13	0.38	0.33
Capex To Depreciation	0.58	1.7	1.08	0.89	4.28	4.49
Pb Ratio	(13.94)	4.06	30.9	2.57	3.41	3.58
Ev To Sales	26.2	7.12	17.85	2.39	10.45	9.93
Free Cash Flow Per Share	1.09	(1.94)	(1.39)	1.4	(0.16)	(0.17)
Roic	0.77	(0.8)	(3.65)	0.13	(0.45)	(0.43)
Payables Turnover	8.24	26.27	29.1	26.53	15.48	15.16
Sales General And Administrative To Revenue	0.64	1.09	0.97	0.21	0.71	1.03
Research And Ddevelopement To Revenue	2.17	2.15	2.52	0.62	2.2	3.42
Capex To Revenue	0.12	0.24	0.16	0.036	0.57	0.6
Cash Per Share	1.9	4.83	2.31	5.39	5.29	2.74
Pocfratio	8.22	(4.95)	(9.09)	5.46	42.1	44.2
Interest Coverage	(194.19)	(241.23)	(50.0)	3.62	(122.41)	(128.53)
Capex To Operating Cash Flow	0.0315	(0.0879)	(0.0692)	0.0621	1.7	1.78
Pfcf Ratio	8.49	(4.55)	(8.5)	5.82	(60.28)	(57.27)
Days Payables Outstanding	44.3	13.9	12.54	13.76	23.58	28.09
Income Quality	(2.18)	0.37	0.88	2.67	(0.19)	(0.18)
Roe	0.76	(2.2)	(3.95)	0.18	(0.43)	(0.45)
Ev To Operating Cash Flow	6.81	(2.6)	(7.59)	4.12	30.96	32.5
Pe Ratio	(18.38)	(1.85)	(7.82)	14.58	(7.91)	(8.31)
Return On Tangible Assets	(0.24)	(0.9)	(0.55)	0.0924	(0.19)	(0.2)
Ev To Free Cash Flow	7.03	(2.39)	(7.1)	4.4	(44.33)	(42.11)
Intangibles To Total Assets	0.007507	0.003585	0.00753	0.004002	0.002986	0.002837
Net Debt To E B I T D A	3.43	3.12	1.47	(2.68)	2.28	1.63
Current Ratio	1.79	3.94	1.6	3.54	2.87	2.1
Tangible Book Value Per Share	(0.67)	2.15	0.36	3.15	2.78	2.91
Receivables Turnover	6.78	10.69	50.97	80.69	9.41	8.94
Graham Number	2.75	15.28	3.61	6.31	8.7	5.07
Shareholders Equity Per Share	(0.67)	2.17	0.38	3.17	2.79	2.93
Capex Per Share	0.0355	0.16	0.0899	0.0925	0.38	0.4
Graham Net Net	(0.84)	1.78	(0.0788)	2.52	1.8	1.89

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Immatics Stock Analysis

When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Immatics Historical Financial Ratios

About Immatics Financial Ratios Analysis

Immatics Biotechnologies Financial Ratios Chart

Price To Sales Ratio

Ptb Ratio

Free Cash Flow Yield

Invested Capital

Immatics Biotechnologies fundamentals Correlations

Immatics Biotechnologies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immatics Biotechnologies fundamentals Accounts

Also Currently Popular

Additional Tools for Immatics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Days Sales Outstanding	+ 0.99	Price To Sales Ratio
Ev To Sales	+ 0.99	Days Sales Outstanding
Free Cash Flow Per Share	+ 0.99	Free Cash Flow Yield
Free Cash Flow Per Share	+ 0.99	Operating Cash Flow Per Share

Average Inventory	- 1.0	Inventory Turnover
Interest Coverage	- 1.0	Ev To Sales
Interest Coverage	- 1.0	Price To Sales Ratio
Interest Coverage	- 0.99	Days Sales Outstanding
Days Payables Outstanding	- 0.98	Average Inventory
Days Payables Outstanding	- 0.98	Payables Turnover